Search the Newsreel

AbbVie Inc. (ABBV) Stock Analysis: Evaluating Growth Potential With A 11.51% Upside

AbbVie Inc. (ABBV) is a biopharmaceutical company with a strong market presence, a current stock price of $246.04, and a potential upside of 11.51% according to analyst ratings. While the company boasts significant revenue growth, strong operational efficiency, and an attractive dividend yield, its …

AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Brokerages

AbbVie Inc. (NYSE:ABBV) has received a "Moderate Buy" consensus rating from 24 brokerages, with an average 12-month price target of $275.70, exceeding its current share price. The company surpassed quarterly earnings expectations with adjusted EPS of $3.65 and revenue of $16.99 billion, marking a …

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie's Q2 Earnings Call AbbVie's second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales growth to strong execution in core immunology therapies, especially SKYRIZI and RINVOQ, and notable …

AbbVie Inc (ABBV) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Análise e Previsão das Ações da AbbVie Inc (ABBV)

St. Louis Financial Planners Asset Management LLC Takes $5.01 Million Position in AbbVie Inc. $ABBV

St. Louis Financial Planners Asset Management LLC has acquired a new position in AbbVie Inc., purchasing 19,202 shares valued at approximately $5.01 million, making AbbVie its seventh-largest holding. This comes as AbbVie reported strong Q2 earnings, exceeding revenue and EPS expectations, though its adjusted …

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …

Projeções de Resultados: AbbVie Inc (ABBV) — LPA e Crescimento de Receita

ABBV6474383 Bond Price and Chart — FINRA:ABBV6474383

This article provides details about the ABBV6474383 bond issued by AbbVie Inc. It lists key terms such as the coupon rate (5.45%), maturity date (September 15, 2038), and outstanding amount. The article also includes company information for AbbVie, Inc., describing it as a research-based …

Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ...

This article first appeared on GuruFocus. Cash Position: Ended Q2 2026 with cash, equivalents, and marketable securities of $106 million. Pro Forma Cash: More than $310 million after receiving a $100 million milestone payment from AbbVie and approximately $108 million in net proceeds from …

AbbVie Inc. (ABBV) Stock forecasts

Argus Research has raised its target price for AbbVie Inc. (ABBV) to $270, noting the company's status as a research-based biopharmaceutical firm spun off from Abbott Laboratories. AbbVie is a component of the S&P 500, with its shares currently trading at $244.93. The report …

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst Topline data from pivotal subretinal wet AMD studies, …

AbbVie Inc. $ABBV Position Raised by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in AbbVie Inc. (ABBV) by 8.2% in the second quarter, bringing its total to 68,002 shares valued at $17.1 million. This increase reflects broader institutional confidence, with hedge funds and institutions collectively owning 70.23% of ABBV stock. The …

AbbVie Inc. Stock 12‑Month Price Target Raised to $275.44, Implies 13% Upside

AbbVie Inc.'s stock 12-month average price target has been increased to $275.44 by 25 analysts, up from $274.04. This new target suggests a potential 13% upside based on the Aug. 4 closing price. The consensus rating from 32 analysts remains "Buy," with 24 Buy …

AbbVie Plans to raise $8 billion to finance deal with Apogee Therapeutics

AbbVie Inc. plans to raise $8 billion through investment-grade bonds to fund its $10.9 billion acquisition of Apogee Therapeutics Inc. This strategic move aims to expand AbbVie's portfolio of anti-inflammatory drugs, particularly with Apogee's zumilokibart, a potential competitor to Sanofi's Dupixent. The acquisition reflects …

What AbbVie’s Q2 Earnings Reveal About the Cost of the Apogee Deal

AbbVie's Q2 2026 earnings beat Street estimates across the board, with revenue reaching $16.99 billion and adjusted EPS at $3.65. However, the positive performance was partially offset by a $0.14 dilution from the pending Apogee Therapeutics acquisition, which reduced the full-year guidance upgrade. Despite …

Is AbbVie’s (ABBV) BOTOX Masseter Bet Quietly Rewriting Its Post-Humira Growth Story?

Prediction: AbbVie Will End The Year at This Price

24/7 Wall St. predicts AbbVie (ABBV) will end the year with a "buy" rating and a price target of $297.71, representing a 20.92% upside from its current price. This optimistic outlook is driven by the strong performance of drugs like Skyrizi and Rinvoq, which …

Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Let's …

Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Central Pacific Bank Trust Division Sells 4,628 Shares of AbbVie Inc. $ABBV

Central Pacific Bank Trust Division significantly reduced its stake in AbbVie Inc. by 44.5% in the second quarter, selling 4,628 shares and retaining 5,766 shares valued at $1.45 million. Despite this sale, AbbVie reported strong second-quarter results with revenue up 10.2% and adjusted EPS …

Canandaigua National Bank & Trust Co. Acquires New Stake in AbbVie Inc. $ABBV

Canandaigua National Bank & Trust Co. has acquired a new stake in AbbVie Inc., purchasing 27,540 shares valued at approximately $6.93 million. This comes as AbbVie reported strong second-quarter results, exceeding analyst expectations with revenue up 10.2% year-over-year and solid EPS. The company also …

AbbVie (ABBV) Wins FDA Review For BOTOX Cosmetic In Jawline Treatment Push

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Allergan Aesthetics, an AbbVie company, reported that the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat …

AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

This article analyzes AbbVie Inc.'s recent earnings beat and the subsequent adjustments made by financial analysts to their future predictions. It will likely cover the company's financial performance, the reasons behind the beat, and how these updated analyst ratings might affect investor sentiment and …

AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition

AbbVie Inc. has initiated a $10 billion bond sale to finance its acquisition of Apogee Therapeutics, as reported by Bloomberg and MT Newswires. This move comes alongside several other recent news items for AbbVie, including positive recommendations for Ubrelvy reimbursement in Canada and FDA …

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share …

AbbVie (ABBV) Lifted Guidance, Has The Market Already Priced It In?

AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal

AbbVie Inc. is reportedly looking to raise at least $8 billion, and potentially up to $10 billion, through an investment-grade bond offering. The pharmaceutical giant intends to use these funds to finance a portion of its acquisition of Apogee Therapeutics Inc. The final size …

Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating

Guggenheim has increased its price target for AbbVie (NYSE: ABBV) to $288 from $261, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst revisions for AbbVie, with Rothschild & Co Redburn also adjusting its target to $285 and Oppenheimer …

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

If approved, BOTOX®Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission is supported by two Phase 3 studies (M21-416 and M21-417), demonstrating statistically significant improvements in masseter muscle …

UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment

UBRELVY®(ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC)is supported by evidence from the pivotal Phase 3 ACHIEVE I and ACHIEVE II studies. CDA-AMC recommendation recognizes the need for additional migraine-specific acute treatment options for adults. Migraine affects an estimated 5 million Canadians with the …

AbbVie’s Growth Now Leans On A Single Molecule

AbbVie's future growth is heavily reliant on a single drug, SKYRIZI, which is projected to account for close to one-third of the company's total revenue in 2026. While the patent for SKYRIZI extends well into the 2030s, the company faces a challenge with its …

AbbVie Inc. stock underperforms Monday when compared to competitors

AbbVie Inc. (ABBV) stock fell 2.33% on Monday, closing at $245.10, despite a generally positive trading session where the S&P 500 and Dow Jones Industrial Average both saw gains. This marks the third consecutive day of losses for AbbVie, underperforming its competitors. The article …

AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says

AbbVie (ABBV) reported another "strong" quarter operationally, with investor attention increasingly PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

AbbVie Inc. 2026: Revenue $16.99B, EPS $2.03— 10-Q Summary

AbbVie Inc. reported its 2026 quarterly results, with revenue reaching $16.99 billion and diluted EPS at $2.03, marking significant growth over the prior year. This performance was attributed to strong sales of key brands like Skyrizi, Rinvoq, and neuroscience products, despite a decline in …

Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026–2036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight

DelveInsight Business Research LLP The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering …